<DOC>
	<DOCNO>NCT01160224</DOCNO>
	<brief_summary>GW766994 selective , competitive antagonist human CC chemokine receptor-3 ( CCR3 ) . It propose inhibition CCR3 receptor may provide treatment airway inflammation asthma . This double-blind , placebo control , parallel group study conduct evaluate effect GW766994 subject mild-moderate asthma high sputum eosinophilia . The primary objective compare effect GW766994 placebo sputum eosinophil .</brief_summary>
	<brief_title>Oral GW766944 ( Oral CCR3 Antagonist )</brief_title>
	<detailed_description>This multi-centre study . This randomized , double-blind , placebo-controlled , parallel-group study , patient asthma eosinophilic bronchitis . Subjects asthma atopic oral prednisone . Inhaled corticosteroid allow stable dose . All subject receive 5 day course 30mg daily oral prednisone one week stop study drug . All subject attend screen ( Visit 1 ) eligibility inclusion assess . Eligible subject randomize receive either 300 mg GW766994 twice daily match placebo Day 1 ( Visit 2 ) stratify accord subject 's sputum eosinophil count Visit 1 . Treatment 10 day oral dosing , subject participate Day 7 8 visit ( Visit 3 ) , Day 10 visit ( Visit 4 - End Treatment ) , follow 1 week wash period ( Visit 5 -Follow Up Visit ) . At Visit 5 , subject give 30 mg oral daily prednisone 5 day subject return clinic Post Oral Prednisone Visit ( Visit 6 ) Day 22 . Pharmacodynamic assessment include sputum blood biomarkers spirometry . Safety assess vital sign measurement , electrocardiogram , clinical laboratory test ( hematology , chemistry &amp; urinalysis ) , clinical monitoring adverse event reporting . Pharmacokinetic sample collect subject accord sample schedule time event table . Study involve sputum biology ( progenitor , cell count ) . Study conduct Canada .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<criteria>Physician diagnosis asthma ( &gt; 12 % improvement FEV1 bronchodilator PC20 methacholine le 8 mg/ml ) document within past 2 year . Males female age â‰¥1875 year inclusive . A female subject eligible participate : Nonchildbearing potential define premenopausal female document tubal ligation hysterectomy ; postmenopausal define 12 month spontaneous amenorrhea [ questionable case blood sample simultaneous follicle stimulate hormone ( FSH ) &gt; 40 MlU/ml estradiol &lt; 40 pg/ml ( &lt; 140 pmol/L ) confirmatory ] . Childbearing potential agrees use one contraception method list Section 9.1 appropriate period time ( determined product label investigator ) prior start dose sufficiently minimize risk pregnancy point . Female subject must agree use contraception 2 day last dose GW766994 . Non smoker . Current smoker pack history le 10 year may enrol study . Subjects use chew tobacco product may enrol discretion Investigator consultation GSK medical monitor . Sputum eosinophils &gt; 4.9 % . AST , ALT , alkaline phosphatase bilirubin &gt; 1.5xULN ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) . QTcB QTcF &lt; 450 msec assess within 6 month screen visit . To eligible , female patient must negative urine pregnancy test . Capable give write informed consent , include compliance requirement restriction list consent form . The subject able understand comply protocol requirement , instruction protocol state restriction . Any clinically relevant abnormality identify screen medical assessment , laboratory examination , ECG . Current smoker . Subjects unable produce technically acceptable sputum sample . Sputum TCC &gt; 25 million cells/g . Clinically significant hepatic impairment current chronic history liver disease know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) Positive HIV , Hepatitis B surface antigen Hepatitis C antibody within 3 month screen . The subject regularly drink 28 unit alcohol week , male 21 unit per week , female . One unit alcohol define medium ( 125ml ) glass wine , half pint ( 250ml ) beer , one measure ( 25ml ) spirit . Pregnant lactating woman . Asthma consider unstable within 2 month prioir screen . Respiratory Infection : Culturedocumented suspect bacterial viral infection upper low respiratory tract , sinus middle ear resolve within 4 week screen lead change asthma management , opinion Investigator expect affect subject asthma status subject ability participate study . Baseline postbronchodilator FEV1 &lt; 50 % predict ( spirometry do screen visit ) . Regular oral prednisone use . Subjects receive therapy monoclonal antibody within proceed 3 month prior screen visit . Comorbidities , investigator 's opinion may interfere study include systemic inflammatory condition rheumatoid arthritis . Donation blood excess 500 mL within 56day period prior dose Participation trial drug within 30 day 5 halflives ( whichever longer ) , participation trial new chemical entity within 2 month prior first dose current study medication , unless opinion Investigator sponsor medication interfere study procedure compromise subject safety . The subject positive prestudy drug/alcohol screen . A minimum list drug screen limited amphetamine , barbiturate , cocaine , opiates , cannabinoids . Subjects use benzodiazepine anxiolytic regular basis include discretion investigator consultation GSK medical monitor . Cytochrome P450 3A4 inhibitor include limited antiretrovirals ( protease inhibitor ) ( e.g.indinavir , nelfinavir , ritonavir , saquinavir ) ; imidazole triazole antifungal ( e.g . ketaconazole , itraconazole ) ; macrolide antibiotic ( e.g . clarithromycin , erytrhomycin ; telithromycin ) ; calcium channel blocker ( diltiazem verapamil ) nefazodone , 6 week . Consumption seville orange , grapefruit grapefruit juice and/or pummelo , exotic citrus fruit , grapefruit hybrid fruit juices 7 day prior first dose study medication . Unwillingness inability follow procedure outline protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Asthma</keyword>
	<keyword>CCR3 receptor antagonist</keyword>
	<keyword>GW766944</keyword>
</DOC>